Tekmira Pharmaceuticals Corp. - Product Pipeline Review - 2014

Published: Jun, 2014 | Pages: 52 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Tekmira Pharmaceuticals Corp. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Tekmira Pharmaceuticals Corp. - Product Pipeline Review - 2014', provides an overview of the Tekmira Pharmaceuticals Corp.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Tekmira Pharmaceuticals Corp.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Tekmira Pharmaceuticals Corp. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Tekmira Pharmaceuticals Corp.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Tekmira Pharmaceuticals Corp.'s pipeline products

Reasons to buy

- Evaluate Tekmira Pharmaceuticals Corp.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Tekmira Pharmaceuticals Corp. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Tekmira Pharmaceuticals Corp.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Tekmira Pharmaceuticals Corp. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Tekmira Pharmaceuticals Corp.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Tekmira Pharmaceuticals Corp. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Tekmira Pharmaceuticals Corp. Snapshot 5
Tekmira Pharmaceuticals Corp. Overview 5
Key Information 5
Key Facts 5
Tekmira Pharmaceuticals Corp. - Research and Development Overview 6
Key Therapeutic Areas 6
Tekmira Pharmaceuticals Corp. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Partnered Products 11
Partnered Products/Combination Treatment Modalities 12
Pipeline Products - Out-Licensed Products 13
Out-Licensed Products/Combination Treatment Modalities 14
Tekmira Pharmaceuticals Corp. - Pipeline Products Glance 15
Tekmira Pharmaceuticals Corp. - Clinical Stage Pipeline Products 15
Phase I Products/Combination Treatment Modalities 15
Tekmira Pharmaceuticals Corp. - Early Stage Pipeline Products 16
Preclinical Products/Combination Treatment Modalities 16
Discovery Products/Combination Treatment Modalities 17
Tekmira Pharmaceuticals Corp. - Drug Profiles 18
TKM-PLK1 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
TKM-100802 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
RNAi Oligonuceotide to Inhibit CSN5 for Cancer 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
RNAi Oligonucleotide for Glycogen Storage Disorder Type IV 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
RNAi Oligonucleotide For Hypertriglyceridemia 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
RNAi Oligonucleotide to Inhibit WEE1 for Hepatocellular Carcinoma 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
RNAi Oligonucleotides for Hepatitis C 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
TKM-100701 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
TKM-ALDH2 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
TKM-HBV 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
TKM-Marburg 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
RNAi Oligonucleotide for Undisclosed Indication 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Tekmira Pharmaceuticals Corp. - Pipeline Analysis 35
Tekmira Pharmaceuticals Corp. - Pipeline Products by Target 35
Tekmira Pharmaceuticals Corp. - Pipeline Products by Route of Administration 36
Tekmira Pharmaceuticals Corp. - Pipeline Products by Molecule Type 37
Tekmira Pharmaceuticals Corp. - Pipeline Products by Mechanism of Action 38
Tekmira Pharmaceuticals Corp. - Recent Pipeline Updates 39
Tekmira Pharmaceuticals Corp. - Dormant Projects 45
Tekmira Pharmaceuticals Corp. - Company Statement 46
Tekmira Pharmaceuticals Corp. - Locations And Subsidiaries 50
Head Office 50
Other Locations & Subsidiaries 50
Appendix 51
Methodology 51
Coverage 51
Secondary Research 51
Primary Research 51
Expert Panel Validation 51
Contact Us 52
Disclaimer 52

List of Tables
Tekmira Pharmaceuticals Corp., Key Information 5
Tekmira Pharmaceuticals Corp., Key Facts 5
Tekmira Pharmaceuticals Corp. - Pipeline by Indication, 2014 8
Tekmira Pharmaceuticals Corp. - Pipeline by Stage of Development, 2014 9
Tekmira Pharmaceuticals Corp. - Monotherapy Products in Pipeline, 2014 10
Tekmira Pharmaceuticals Corp. - Partnered Products in Pipeline, 2014 11
Tekmira Pharmaceuticals Corp. - Partnered Products/ Combination Treatment Modalities, 2014 12
Tekmira Pharmaceuticals Corp. - Out-Licensed Products in Pipeline, 2014 13
Tekmira Pharmaceuticals Corp. - Out-Licensed Products/ Combination Treatment Modalities, 2014 14
Tekmira Pharmaceuticals Corp. - Phase I, 2014 15
Tekmira Pharmaceuticals Corp. - Preclinical, 2014 16
Tekmira Pharmaceuticals Corp. - Discovery, 2014 17
Tekmira Pharmaceuticals Corp. - Pipeline by Target, 2014 35
Tekmira Pharmaceuticals Corp. - Pipeline by Route of Administration, 2014 36
Tekmira Pharmaceuticals Corp. - Pipeline by Molecule Type, 2014 37
Tekmira Pharmaceuticals Corp. - Pipeline Products by Mechanism of Action, 2014 38
Tekmira Pharmaceuticals Corp. - Recent Pipeline Updates, 2014 39
Tekmira Pharmaceuticals Corp. - Dormant Developmental Projects,2014 45
Tekmira Pharmaceuticals Corp., Subsidiaries 50